Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

It’s no secret that obesity is becoming an epidemic in the United  States. It’s estimated that by 2030, 50 percent of ...

FuturHealth offers personalized weight-loss guidance and medications with the help of licensed dietitians and doctors. These include GLP-1 agonists such as semaglutide -- better known as Ozempic. The ...

Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Two new studies that have been published recently show that people who have been taking weight loss drugs may have encountered an increased risk of serious eye conditions and vision loss.

WITH the price of Mounjaro set to rise and concerns about long-term affordability and access, many may be looking to turn to alternative treatments, like Wegovy. But how do the two weight loss ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

A WOMAN who’s lost almost five stone on Mounjaro has admitted she’s willing to get herself into debt to stay on it amid the ...

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...